Free Trial
→ A simple options setup that cuts through the noise (From TradeWins) (Ad)tc pixel
NYSE:DNA

Ginkgo Bioworks Q3 2026 Earnings Report

Ginkgo Bioworks logo
$11.22 -0.25 (-2.14%)
As of 12:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Ginkgo Bioworks EPS Results

Actual EPS
N/A
Consensus EPS
-$0.58
Beat/Miss
N/A
One Year Ago EPS
N/A

Ginkgo Bioworks Revenue Results

Actual Revenue
N/A
Expected Revenue
$21.57 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ginkgo Bioworks Announcement Details

Quarter
Q3 2026
Date
11/5/2026
Time
Before Market Opens
Conference Call Date
Thursday, November 5, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Ginkgo Bioworks Earnings Headlines

Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
October 8 at 6:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/araceli-biosciences-and-ginkgo-bioworks-bring-cellular-imaging-at-scale-to-nebulas-lab-in-the-loop-302901742.html
Ginkgo Bioworks: The Valuation Has Outrun The Business
October 7 at 11:06 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4952555-ginkgo-bioworks-the-valuation-has-outrun-the-business
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
October 8 at 1:00 AM  |  Paradigm Press (Ad)
Ginkgo Bioworks (NYSE:DNA) Reaches New 12-Month High - Here's What Happened
October 6 at 11:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31092296
Ginkgo Bioworks (NYSE:DNA) Sees Strong Trading Volume - Should You Buy?
October 5 at 1:14 PM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088413
Ginkgo Bioworks (NYSE:DNA) Stock Sees Unusually High Call Option Buying
October 5 at 12:41 PM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088085
See More Ginkgo Bioworks Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ginkgo Bioworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ginkgo Bioworks and other key companies, straight to your email.

About Ginkgo Bioworks

Ginkgo Bioworks (NYSE:DNA), Inc. is a biotechnology company that develops biological engineering technologies and services. Its platform is designed to help customers program cells and microorganisms to produce products or perform functions for applications in areas such as pharmaceuticals, agriculture, food, chemicals and materials.

The company combines biological research, laboratory automation, genetic engineering, data analysis and software through its cell-programming platform and foundry operations. Ginkgo also provides biosecurity and biological monitoring services, including offerings intended to help detect and analyze biological threats and support public-health preparedness.

Ginkgo was founded in 2008 by a group that included Jason Kelly, Reshma Shetty, Barry Canton, Austin Che and Tom Knight. The company is headquartered in Boston and works with organizations in the United States and internationally. Jason Kelly is a co-founder and has served as the company’s chief executive officer.

View Ginkgo Bioworks Profile
Earnings Tools